hi,
ist zwar eine etwas provokante überschrift, aber der wert geron (gern) wird in naher zukunft durch die decke gehen.
ich rechne mit der rally in ca. 1 jahr, könnte auch erst in 11/2 jahren bis 2 jahren sein.
der grund liegt darin, dass geron noch sehr geringe umsätze generiert, da das geschäft mit dem klonen sich erst ab 2004/2005 etablieren wird.
werte wie z.B. amgn, vrtx, mlnm stellen die ersten stufe der biotechnologie dar, der medikamentenentwicklung.
geron ist eine stufe über diesen unternehmen anzusiedeln.
Ab 2004/2005 wird geron beträchtliche umsätze erzielen und spätestens dann wird geron 10mal höher bewertet sein.
bei einer jetzigen MK von 500 millionen dollar sollte man seine ersten positionen aufbauen, aber nur diejenigen von euch, die an das klonen glauben.
DAS KLONEN WIRD SICH DURCHSETZEN UND GERON IST DER BRANCHENPRIMUS!!
JEDOCH BEDENKT,DASS DIESES INVESTMENT MIT GRÖßEREN RISIKEN BEHAFTET IST!!
bye..
Geron Corporation
230 Constitution Dr.
Menlo Park, CA 94025 Phone: 650-473-7700
Fax: 650-473-7701
http://www.geron.com
Geron (from the Greek word for old man) studies the aging process, focusing on telomeres, structures that act as a molecular clock for cellular aging, and telomerase, an enzyme that may prolong the cellular life span. Geron hopes to make cancerous cells age and die. Its research has applications in skin aging, heart and liver disease, and Parkinson`s disease. The firm is also studying how to use cloned pigs as sources for human organ transplants. Geron partners with Celera Genomics (stem cell research), Pharmacia & Upjohn, and Roslin Institute. A Scottish firm that helped clone Dolly the sheep is now Geron`s subsidiary, Geron Bio-Med. Geron received the first patent for cloning human embryos from the UK government.
Key People
President and CEO: Thomas B. Okarma, age 54, $319,130 pay
SVP, Corporate Development, CFO, Secretary, and Treasurer: David L. Greenwood, age 48, $275,900 pay
VP, Cell and Gene Therapies: Jane S. Lebkowski, age 44, $199,263 pay
VP, Drug Discovery: Richard L. Tolman, age 58, $208,837 pay
VP Intellectual Properties: Nancy Robinson
Key Numbers
Type: Public Company
Nasdaq: GERN
Fiscal Year-End: December
1999 Sales (mil.): $5.4
1-Yr. Sales Growth: (20.6)%
1999 Net Inc. (mil.): ($46.4)
1-Yr. Net Inc. Growth: --
1999 Employees: 103
Top Officers
CEO: Thomas B. Okarma
CFO: David L. Greenwood
HR: Jeanine Niacaris
Top Competitors
Nexell Therapeutics
SUGEN
Shire Pharmaceuticals Group
Annual Financials
Income Statement
All dollar amounts in million
except per share amounts. Dec 99 Dec 98 Dec 97
Revenue 5.4 6.8 7.3
Cost of Goods Sold 0.0 0.0 0.0
Gross Profit 5.4 6.8 7.3
Gross Profit Margin 100.0% 100.0% 100.0%
SG&A Expense 26.2 19.4 18.2
Operating Income (20.8) (12.6) (10.9)
Operating Margin -- -- --
Total Net Income (46.4) (10.8) (9.6)
Net Profit Margin -- -- --
Diluted EPS ($) (3.00) (1.00) (0.91)
Balance Sheet Dec 99 Dec 98 Dec 97
Cash 7.8 16.4 4.1
Net Receivables 0.7 0.5 0.9
Inventories 0.0 0.0 0.0
Total Current Assets 40.4 25.8 23.5
Total Assets 63.7 44.5 26.1
Short-Term Debt 1.2 0.9 1.0
Total Current Liabilities 7.9 3.6 3.7
Long-Term Debt 17.1 8.1 1.3
Total Liabilities 37.4 11.7 5.0
Total Equity 26.2 32.8 21.1
Shares Outstanding (mil.) 17.4 13.7 10.8
Quarterly Financials
Income Statement
All dollar amounts in million
except per share amounts. Quarter
Ending
Jun. 2000 Quarter
Ending
Mar. 2000 Quarter
Ending
Dec. 1999 Quarter
Ending
Sep. 1999 Quarter
Ending
Jun. 1999
Revenue 1.8 1.3 1.3 1.3 1.3
Cost of Goods Sold 0.0 0.0 0.0 0.0 0.0
Gross Profit 1.8 1.3 1.3 1.3 1.3
Gross Profit Margin 100.0% 100.0% 100.0% 100.0% 100.0%
SG&A Expense 8.4 8.3 6.6 8.2 5.9
Operating Income (6.6) (7.0) (5.3) (6.9) (4.6)
Operating Margin -- -- -- -- --
Total Net Income (16.5) (6.6) (8.1) (6.9) (28.0)
Net Profit Margin -- -- -- -- --
Diluted EPS ($) (0.77) (0.35) (0.45) (0.42) (1.87)
Balance Sheet Jun. 2000 Mar. 2000 Dec. 1999 Sep. 1999 Jun. 1999
Cash 74.4 52.5 7.8 27.8 19.4
Net Receivables 0.5 1.0 0.7 0.6 0.6
Inventories 0.0 0.0 0.0 0.0 0.0
Total Current Assets 76.1 56.5 40.4 42.9 27.9
Total Assets 119.3 98.5 63.7 68.2 62.2
Short-Term Debt 4.2 1.1 1.2 1.2 1.1
Total Current Liabilities 8.3 8.7 7.9 6.8 7.8
Long-Term Debt 32.8 7.9 17.1 21.9 11.4
Total Liabilities 52.7 28.8 37.4 42.9 33.5
Total Equity 66.7 69.7 26.2 25.3 28.7
Shares Outstanding (mil.) 21.6 21.4 17.4 16.8 16.5
Some financial information provided by Media General Financial Services, Inc., Richmond, Virginia
Hoover`s Company Information
Copyright © 2000, Hoover`s, Inc.
http://www.hoovers.com